| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
|
N Engl J Med
|
2008
|
9.20
|
|
2
|
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
|
Cancer Discov
|
2011
|
4.80
|
|
3
|
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
|
Nat Genet
|
2013
|
4.35
|
|
4
|
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
|
J Clin Oncol
|
2005
|
4.24
|
|
5
|
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
|
Clin Cancer Res
|
2009
|
3.45
|
|
6
|
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.
|
Nat Genet
|
2013
|
3.42
|
|
7
|
Drug-sensitive FGFR2 mutations in endometrial carcinoma.
|
Proc Natl Acad Sci U S A
|
2008
|
3.30
|
|
8
|
Genome-wide association study identifies a common variant associated with risk of endometrial cancer.
|
Nat Genet
|
2011
|
1.84
|
|
9
|
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.
|
Nat Commun
|
2013
|
1.73
|
|
10
|
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
|
Cancer Cell
|
2011
|
1.40
|
|
11
|
Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer.
|
J Clin Oncol
|
2004
|
1.39
|
|
12
|
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
|
Nat Commun
|
2013
|
1.36
|
|
13
|
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
|
Clin Cancer Res
|
2012
|
1.35
|
|
14
|
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer.
|
PLoS Genet
|
2012
|
1.33
|
|
15
|
Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.
|
Clin Cancer Res
|
2013
|
1.21
|
|
16
|
Vascular proliferation is important for clinical progress of endometrial cancer.
|
Cancer Res
|
2006
|
1.19
|
|
17
|
Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.
|
Clin Cancer Res
|
2011
|
1.19
|
|
18
|
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
|
Eur J Cancer
|
2011
|
1.19
|
|
19
|
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
|
Eur J Cancer
|
2013
|
1.17
|
|
20
|
GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
|
Am J Obstet Gynecol
|
2008
|
1.15
|
|
21
|
Biologic markers in endometrial cancer treatment.
|
APMIS
|
2009
|
1.12
|
|
22
|
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development.
|
PLoS Med
|
2013
|
1.10
|
|
23
|
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
|
Gynecol Oncol
|
2012
|
1.06
|
|
24
|
Onconeural antibodies in sera from patients with various types of tumours.
|
Cancer Immunol Immunother
|
2009
|
1.06
|
|
25
|
Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers.
|
Cancer Res
|
2002
|
1.03
|
|
26
|
Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer.
|
Clin Cancer Res
|
2011
|
1.03
|
|
27
|
Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.
|
PLoS One
|
2013
|
1.02
|
|
28
|
Genome-wide association study identifies a possible susceptibility locus for endometrial cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
1.02
|
|
29
|
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.
|
Hum Genet
|
2013
|
0.99
|
|
30
|
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
|
Clin Cancer Res
|
2013
|
0.97
|
|
31
|
Lipocalin 2 expression is associated with aggressive features of endometrial cancer.
|
BMC Cancer
|
2012
|
0.92
|
|
32
|
Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.
|
Am J Obstet Gynecol
|
2006
|
0.92
|
|
33
|
Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique.
|
Cancer Immunol Immunother
|
2006
|
0.92
|
|
34
|
A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissue.
|
PLoS One
|
2011
|
0.92
|
|
35
|
MSI-low, a real phenomenon which varies in frequency among cancer types.
|
J Pathol
|
2003
|
0.91
|
|
36
|
CDR2 antigen and Yo antibodies.
|
Cancer Immunol Immunother
|
2010
|
0.91
|
|
37
|
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
|
J Natl Cancer Inst
|
2015
|
0.90
|
|
38
|
Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting.
|
Am J Obstet Gynecol
|
2009
|
0.90
|
|
39
|
Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk.
|
Hum Genet
|
2014
|
0.89
|
|
40
|
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.
|
Cancer Res
|
2013
|
0.89
|
|
41
|
Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study.
|
Clin Cancer Res
|
2002
|
0.89
|
|
42
|
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
|
Cancer
|
2013
|
0.89
|
|
43
|
Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists.
|
Eur Radiol
|
2012
|
0.88
|
|
44
|
Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients.
|
Int J Cancer
|
2006
|
0.88
|
|
45
|
HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
|
Int J Oncol
|
2008
|
0.88
|
|
46
|
Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma.
|
Histopathology
|
2009
|
0.88
|
|
47
|
Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer.
|
Am J Pathol
|
2011
|
0.87
|
|
48
|
Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas.
|
Gynecol Oncol
|
2013
|
0.87
|
|
49
|
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer.
|
Mol Cancer
|
2014
|
0.87
|
|
50
|
Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.
|
Anal Biochem
|
2007
|
0.86
|
|
51
|
Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence.
|
Eur Radiol
|
2013
|
0.86
|
|
52
|
Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective.
|
Gynecol Oncol
|
2012
|
0.86
|
|
53
|
ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
|
Mod Pathol
|
2012
|
0.84
|
|
54
|
GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer.
|
Int J Gynecol Cancer
|
2013
|
0.84
|
|
55
|
Follow-up routines in gynecological cancer - time for a change?
|
Acta Obstet Gynecol Scand
|
2011
|
0.84
|
|
56
|
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
|
PLoS One
|
2012
|
0.84
|
|
57
|
Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas.
|
Gynecol Oncol
|
2012
|
0.84
|
|
58
|
Parity and time interval since childbirth influence survival in endometrial cancer patients.
|
Int J Gynecol Cancer
|
2009
|
0.83
|
|
59
|
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
|
Oncotarget
|
2014
|
0.82
|
|
60
|
Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas.
|
Int J Gynecol Cancer
|
2015
|
0.81
|
|
61
|
Polymorphisms in inflammation pathway genes and endometrial cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.81
|
|
62
|
Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
|
Biochim Biophys Acta
|
2013
|
0.80
|
|
63
|
Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas.
|
Histopathology
|
2011
|
0.79
|
|
64
|
Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis.
|
Gynecol Oncol
|
2003
|
0.79
|
|
65
|
Plasma calprotectin concentrations in women with endometrial carcinoma.
|
Gynecol Oncol
|
2009
|
0.78
|
|
66
|
Follow-up of gynecological cancer patients after treatment - the views of European experts in gynecologic oncology.
|
Acta Obstet Gynecol Scand
|
2012
|
0.78
|
|
67
|
Prognostic impact of parity in 493 uterine sarcoma patients.
|
Int J Gynecol Cancer
|
2009
|
0.78
|
|
68
|
Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.
|
Mol Nutr Food Res
|
2014
|
0.77
|
|
69
|
Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer.
|
Histopathology
|
2010
|
0.77
|
|
70
|
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era.
|
Int J Gynecol Cancer
|
2013
|
0.77
|
|
71
|
[Late, but good].
|
Tidsskr Nor Laegeforen
|
2008
|
0.75
|
|
72
|
Subspecialist training in surgical gynecologic oncology in the Nordic countries.
|
Acta Obstet Gynecol Scand
|
2011
|
0.75
|
|
73
|
Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.
|
Sci Rep
|
2016
|
0.75
|
|
74
|
Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.
|
Sci Rep
|
2017
|
0.75
|